Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

In the era of DAAs, adherence is paramount to treatment success given the strict dosing regimen of first generation HCV protease inhibitors (PIs). First generation DAAs have high pill burdens and ...

an oral NS5A inhibitor, for the treatment of hepatitis c virus (HCV) infection. Study authors outline the sequences of atomic resolution required to convert bemnifosbuvir (AT-527) into its active ...

About Bemnifosbuvir and Ruzasvir for Hepatitis C Virus (HCV) Bemnifosbuvir, an oral HCV NS5B inhibitor, has been shown in in vitro studies to be approximately 10-fold more active than sofosbuvir ...

hepatitis C virus; mRNA, messenger RNA; PI, protease inhibitor; NS, nonstructural protein; RdRp, RNA-dependent RNA polymerase; —, no drugs in this class in this phase of development.

Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.

We are pleased to be assessing nimacimab as a monotherapy but to also undertake a preliminary evaluation of our peripheral CB1 inhibitor in combination with a GLP-1 drug.” “As we evaluate CB1 ...

HIV symptoms vary by stage of infection. There are three stages: primary infection (Stage 1), clinical latency (Stage 2), and AIDS (Stage 3). During primary infection, the symptoms are caused by the ...